EAN NewsResearch
EU Commission approves Leqembi (Lecanemab) for treatment of early-stage Alzheimer’s disease
Following an earlier decision by the EMA, the EU Commission has granted EU authorisation for Lecanemab to treat mild cognitive impairment in the early stages of Alzheimer’s disease.